Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose aflibercept versus aflibercept 2 mg in neovascular age-related macular degeneration
jRCT2080225260Phase 3Completed
- Sponsor
- Bayer
- Start
- Jul 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of aflibercept in exudative macular degeneration (2 arms), sponsored by Bayer. Primary endpoint: Change in best-corrected visual acuity (BCVA) from baseline at Week 48. Started Jul 2020; status: completed.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on jRCT2080225260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225260.